Celsion to Present Two Posters with Data of GEN-1 in Ovarian Cancer at ASCO Meeting

Celsion to Present Two Posters with Data of GEN-1 in Ovarian Cancer at ASCO Meeting
Celsion Corporation will present two posters with key findings of its IL-12 gene-mediated immunotherapy, GEN-1, in ovarian cancer. The presentations will be made at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium in Orlando, Fla., Feb. 23-25. The first poster, titled “Phase I study and activity of formulated IL-12 plasmid administered intraperitoneally in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer,” will report clinical results from the OVATION Study. The Phase 1b dose-escalating clinical trial (NCT02480374) is testing GEN-1 administered in combination with standard neoadjuvant (pre-surgery) chemotherapy in patients newly diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer, who will undergo interval debulking surgery. The second poster, titled “Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer,” will report translational data from the OVATION Study and previous GEN-1 clinical trials. The OVATION Study has four dose groups meant to enroll three to six patients each, to identify a safe, tolerable, and effective dose of GEN-1. The first three groups enrolled three patients each and provided
Subscribe or to access all post and page content.